AstraZeneca Appeals IRA Loss, Reiterates Constitutional Challenge to Drug Price Negotiations

1. AstraZeneca's Appeal: AstraZeneca has appealed a federal court decision that dismissed its lawsuit challenging the constitutionality of the Medicare Drug Price Negotiation Program under the Inflation Reduction Act (IRA).
2. Constitutional Claims: AstraZeneca alleges that the Negotiation Program violates its Fifth Amendment due process rights and is thus unconstitutional.
3. Court Ruling: The court dismissed AstraZeneca's suit, finding that the manufacturer's purported property interest in selling drugs at market prices was not protected by the Fifth Amendment.
4. Other Lawsuits: Similar lawsuits have been filed by other manufacturers, including Bristol Myers Squibb and Johnson & Johnson, which were also dismissed by courts in the Third Circuit.
5. Program Implementation: The Medicare Drug Price Negotiation Program is set to begin in 2026, with the first 10 negotiation-eligible drugs selected by the Centers for Medicare and Medicaid Services (CMS).